Pre-made Bococizumab biosimilar ( Whole mAb, anti-PCSK9 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-077
Anti-PCSK9 therapeutic antibody (Pre-made Bococizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PCSK9 therapeutic antibody (Pre-made Bococizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||3sqo:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia|